The First Affiliated Hospital of Zhengzhou University, Zhengzhou, 450052, People's Republic of China.
Henan Bioengineering Technology Reseach Center, Zhengzhou, 450010, People's Republic of China.
Sci Rep. 2022 Jun 16;12(1):10082. doi: 10.1038/s41598-022-14097-x.
Bladder cancer (BLCA) is one of the most frequent genitourinary cancers, with a high rate of morbidity and mortality. The connection of m6A-related lncRNAs with PD-L1 and tumor immune microenvironment (TIME) in BLCA prognosis was extensively investigated in this study, which could suggest novel therapeutic targets for further investigation. 30 m6A-associated lncRNAs with predictive values from the TCGA data set were identified with co-expression analysis. Cluster2 was correlated with a poor prognosis, upregulated PD-L1 expression, and higher immune ratings. Cluster2 had larger amounts of resting CD4 memory-activated T cells, M2 macrophages, neutrophils, and NK cells infiltration. "CHEMOKINE SIGNALING PATHWAY" was the most significantly enriched signaling pathway according to GSEA, which may play an important role in the different immune cell infiltrates between cluster1/2. The risk model for m6A-related lncRNAs could be employed in a prognostic model to predict BLCA prognosis, regardless of other clinical features. Collectively, m6A-related lncRNAs were linked to PD-L1 and TIME, which would dynamically affect the number of tumor-infiltrating immune cells. m6A-related lncRNAs may be key mediators of PD-L1 expression and immune cells infiltration and may strongly affect the TIME of BLCA.
膀胱癌(BLCA)是最常见的泌尿生殖系统癌症之一,发病率和死亡率都很高。本研究广泛探讨了 m6A 相关 lncRNAs 与 BLCA 预后中 PD-L1 和肿瘤免疫微环境(TIME)的关系,这可能为进一步研究提供新的治疗靶点。通过共表达分析,从 TCGA 数据集确定了具有预测价值的 30 个 m6A 相关 lncRNAs。Cluster2 与预后不良、PD-L1 表达上调和更高的免疫评分相关。Cluster2 中静止的 CD4 记忆激活 T 细胞、M2 巨噬细胞、中性粒细胞和 NK 细胞浸润较多。根据 GSEA,“趋化因子信号通路”是最显著富集的信号通路,它可能在 cluster1/2 之间不同的免疫细胞浸润中起重要作用。m6A 相关 lncRNAs 的风险模型可用于预测 BLCA 预后的预后模型,而无需考虑其他临床特征。总之,m6A 相关 lncRNAs 与 PD-L1 和 TIME 相关,可动态影响肿瘤浸润免疫细胞的数量。m6A 相关 lncRNAs 可能是 PD-L1 表达和免疫细胞浸润的关键介质,并可能强烈影响 BLCA 的 TIME。